Symbol

Quantity

Purchase Price Per Share

Total Cost 

Current Quote

Barchart Link

Stock Weekly 

News

14

EARS

1. This company has been in existence since 2015.
2. This company has had several stock splits.
3. Mar 14, 2018
   10/1 Stock Split
4. Apr 30, 2019
   1/1 Stock Split
5. May 01, 2019
   20/1 Stock Split

6. The 1 analysts offering 12-month price forecasts for Auris Medical Holding Ltd have a median target of 14.42, with a high estimate of 14.42 and a low estimate of 14.42. The median estimate represents a +452.58%increase from the last price of 2.61.

   Analyst Recommendations
   The current consensus among 1 polled investment analysts is to buy stock in Auris Medical Holding Ltd. This rating has held steady since July, when it was unchanged from a buy rating.Move your mouse over past
   months for detail

    

7. The Current status is a sell signal, I believe we should hold.

0

ECTYQ

No longer a Valid Stock 

15

EYES 

1.  This stock has been around since 2015.
2. At its hight, it was around 16 and the low 0.69.
3. The current consensus is a sell signal also some recommend holding
4. Researchers Present Latest Positive Results of Second Sight’s Orion Visual Cortical Prosthesis Feasibility StudyBusinessWire – Tue Jun 25, 3:05PM CDT

   Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics intended to create an artificial form of useful…

5.  

   .

The 1 analysts offering 12-month price forecasts for Second Sight Medical Products Inc have a median target of 2.50, with a high estimate of 2.50 and a low estimate of 2.50. The median estimate represents a +220.18%increase from the last price of 0.78.

Analyst Recommendations

The current consensus among 1 polled investment analysts is to buy stock in Second Sight Medical Products Inc. This rating has held steady since July, when it was unchanged from a buyrating.Move your mouse over past
months for detail

 

I believe we should hold might have a potential in the long term.

 

16

EYESW

1. Company has been around since 2017.
2. At its height was 0.84 and the low was 0.15.
3. The current signal is a weak buy
4. There is not much info available on this stock at this time.
5. I would recommend selling when it hits 0.30

17

FLWPF

1. This company has been around since Nov 2018.
2. The highest price was 5 and now it at its lowest
3. SELL

   The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

4. Great news today! Flowr products are on the shelves at some of the big dispensaries.
5. The Flowr Corporation Joins Shoppers Drug Mart and TruTrace Technologies Pilot Program for Validation of Medical Cannabis

6. The Flowr Corporation Announces Public Offering of Common Shares for Approximately C$125 Million It seems the company is trying to raise money

7. Flowr Withdraws $95M Offering, Announces Smaller Capital Raise

8.  

18

FTSSF

1. This company has been around since Apr 2017.
2. At its highest sold for 1.10 and currently is at its lowest.
3. Current indicators for this stock are strong sell.
4. First Cobalt and Glencore Conclude Term Sheet for Refinery Restart
5. 

19

GERN

1. This company has been around since 1997.
2. At its hight, it sold for 50. and currently, sell for 1.15
3. Barchart and other indicators recommend sell.
4. The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction. Other indicators have different opinions.

5. The 3 analysts offering 12-month price forecasts for Geron Corp have a median target of 4.00, with a high estimate of 4.50 and a low estimate of 3.00. The median estimate represents a +247.83% increase from the last price of 1.15.

   

   Analyst Recommendations

   The current consensus among 3 polled investment analysts is to buy stock in Geron Corp. This rating has held steady since July, when it was unchanged from a buy rating.Move your mouse over past
   months for detail

   
   Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline

   Jul 23 / Zacks.com – Paid Partner Content

20

GNCA

1. This company has been around since March 2014.
2. At its peak sold for 154 now is around 3.03.

3. The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

   The 4 analysts offering 12-month price forecasts for Genocea Biosciences Inc have a median target of 15.50, with a high estimate of 32.00 and a low estimate of 13.00. The median estimate represents a +411.55%increase from the last price of 3.03.

   

   Analyst Recommendations

   The current consensus among 4 polled investment analysts is to buy stock in Genocea Biosciences Inc. This rating has held steady since July, when it was unchanged from a buy rating.Move your mouse over past
   months for detail

   

    

   Geron Enhances Oncology Expertise to Advance Corporate ObjectivesGlobeNewswire – Thu Jul 18, 3:15PM CDT

   Chats:

   According to an application I use, on 7/19/19, 7 insiders bought GNCA shares. Each bought bought 5,625 shares at $3.66 per share 

   WSJ reports 9 insiders bought $90mm in stock. Impressive vote of confidence.Their results are impressive. 

   I think we should hold on to this stock.

21

GNNSF

1. This company has been around since Oct 2017
2. At its pick sold for 3.6 currently, it is at 2.20.
3. GenScript Biotech’s Biologics R&D and production center is formally put into operationPR Newswire – Wed Jul 17, 8:32PM CDT

   GenScript Biotech Corp., one of the leading Biologics contract development and manufacturing organizations (CDMOs) in China, today announced that its Biologics research and development (R&D) and production…

    GNNSF : 2.2000 (-9.84%)
   Chinese CDMO GenScript starts construction of GenScript-Legend Biotech Commercial Manufacturing CenterPR Newswire – Mon Apr 15, 3:47AM CDT

   GenScript Biotech Corp, a leading Chinese bio-pharmaceutical contract development and manufacturing organization (CDMO), held the groundbreaking ceremony for the start of construction of the GenScript-Legend…

    GNNSF : 2.2000 (-9.84%)
   I think we should hold on to the stock for a bit longer.

22

HERB

1. Company has been around since 2004.
2. At its height sold for 6.00 currently, it is at its lowest.

3. The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

   

This company is in limbo, no major news or activities.

23

HRVOF

1. This company has been around since Jun 2017.
2. The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.
3. 

    
   09/26/2018Open$0.613High$0.622Low$0.5973Close$0.61Volume32,311

   No conversations or major news in March this year there was a major insider purchase.